Bespak

What Bespak does

Bespak is a specialist inhalation contract development and manufacturing organization (CDMO) headquartered in King's Lynn, United Kingdom, with manufacturing operations at two UK sites in Holmes Chapel and King's Lynn. Founded in 1998, the company employs 501-1,000 people and focuses on the manufacture of pressurized metered dose inhalers (pMDIs), including bronchodilator formulations such as albuterol sulfate MDIs. Bespak's core technical capability is the production of pMDIs using next-generation HFO-1234ze low global warming potential propellant, which enables up to 90% carbon footprint reduction versus traditional CFC-based inhalers, positioning the company in the structural CFC phase-out market transition.

Bespak generates revenue through contract manufacturing fees paid by pharmaceutical clients for inhalation device development and production services, operating as a B2B enterprise CDMO with direct sales relationships. Its largest disclosed customer is Chiesi Group, with whom it has expanded a strategic partnership (announced March 11, 2026) for the Carbon Minimal Inhaler program. The company also partners with DevPro on eco-friendly inhaler development. Bespak holds Science Based Targets initiative (SBTi) validated decarbonization targets and has conducted proprietary Supply Chain Biodiversity Footprinting (SCBF) assessments at its UK sites, giving it regulatory-aligned sustainability credentials that are increasingly relevant under EU CSRD, UK Environment Act, and Global Biodiversity Framework reporting requirements.

The company is actively expanding capacity, with a 2025-2026 Holmes Chapel facility expansion adding new production lines and 150 jobs. Bespak is privately held with no disclosed parent company, institutional investors, or public ownership structure based on the available source material. The firm's go-to-market is enterprise field sales targeting large pharmaceutical companies requiring specialized inhalation device manufacturing with low-carbon solutions.

Name

Bespak

Website

https://bespak.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bespak is a UK-based specialist inhalation CDMO manufacturing pressurized metered dose inhalers (pMDIs), including low-GWP HFO-1234ze propellant inhalers, for large pharmaceutical clients such as Chiesi through direct contract manufacturing partnerships.

Ownership category

akta.pro rank

Product category

Inhalation Drug Delivery Device Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Measuring, Dispensing, and Other Pumping Equipment Manufacturing (333914)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Inhalers (MDI/DPI/SMI) (HLAHAIAI)

akta.pro secondary industries

Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers) (HLAHAGAK)

Keywords

• Inhalation drug delivery
• Pressurized metered dose inhalers
• Contract manufacturing organization
• Pharmaceutical device manufacturing
• Low-GWP propellant inhalers

Headquarters

HQ city

Lynn

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Infrastructure, Personnel, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Bespak operates as a contract development and manufacturing organization (CDMO) providing inhalation device manufacturing services to pharmaceutical companies. Revenue is generated through manufacturing fees for producing pressurized metered dose inhalers and related drug delivery devices under contract with pharmaceutical clients.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Bespak is a specialist inhalation contract development and manufacturing organization (CDMO) that develops and produces pressurized metered dose inhalers (pMDIs) and related drug delivery devices for pharmaceutical companies. Its core service encompasses end-to-end inhalation device manufacturing at its two UK sites in Holmes Chapel and King's Lynn, with a distinctive focus on low-global-warming-potential propellant (HFO-1234ze) inhalers that reduce pMDI carbon footprint by up to 90% compared to traditional CFC-based devices.

Product overview

Bespak is a specialist inhalation contract development and manufacturing organization operating two UK manufacturing sites in Holmes Chapel and King's Lynn. The company operates as a single-product-focused manufacturer specializing in pressurized metered dose inhalers (pMDIs), including bronchodilator formulations. Bespak's core offering centers on pMDI manufacturing, augmented by an eco-friendly product line using low-GWP propellants (HFO-1234ze) developed through the Carbon Minimal Inhaler program partnership with Chiesi Group. The company's sustainability initiatives include validated decarbonization targets approved by the Science Based Targets initiative and biodiversity footprinting assessments at its UK manufacturing facilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Pressurized Metered Dose Inhalers (pMDIs) Contract-manufactured pressurized metered dose inhalers (pMDIs), including bronchodilator formulations such as albuterol sulfate MDIs, produced for large pharmaceutical clients at Bespak's UK manufacturing sites in Holmes Chapel and King's Lynn.
• Low-GWP Propellant Inhalers (HFO-1234ze) Eco-friendly pressurized metered dose inhalers manufactured using HFO-1234ze, a low global warming potential propellant. These inhalers significantly reduce the carbon footprint of pMDIs compared to traditional CFC-based inhalers while maintaining patient treatment options, and are offered to pharmaceutical clients as part of Bespak's contract manufacturing portfolio.
• Carbon Minimal Inhaler (CMI) Program Manufacturing A contract manufacturing program operated in partnership with Chiesi Group to produce low-carbon pressurized metered dose inhalers using low global warming potential propellants, targeting up to 90% reduction in pMDI carbon footprint. The program supports Chiesi's Net Zero by 2035 commitment and is delivered from Bespak's expanded Holmes Chapel manufacturing facility.

Quantifiable outcome

• Up to 90% carbon footprint reduction in pMDIs through transition to low-GWP propellants
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core and minor.

• ChiesicoreStrategic or Co-development Partner · 11 March 2026Chiesi and Bespak expanded their partnership on March 11, 2026, to increase pressurized metered dose inhaler manufacturing capacity at Bespak's Holmes Chapel site. This collaboration supports Chiesi's Carbon Minimal Inhaler program, aiming to reduce the carbon footprint of pMDIs by up to 90% through transition to low global warming potential propellants. The partnership reinforces both companies' sustainability commitments, with Chiesi targeting Net Zero by 2035 and Bespak holding validated decarbonization targets approved by the Science Based Targets initiative.
• DevProminorStrategic or Co-development PartnerBespak and DevPro are developing eco-friendly inhalation solutions using HFO-1234ze propellant, targeting the transition to environmentally sustainable metered dose inhalers in line with CFC phase-out requirements.

Scale indicators1 record

Recent moves7 records

Expansion highlights4 records

Direct peers

• Hovione: Hovione is a specialty CDMO with strong inhalation drug delivery capabilities including pMDI, DPI, and nasal spray development and manufacturing. Directly comparable to Bespak as a contract manufacturer serving pharmaceutical clients with inhalation device expertise.
• Aptar Pharma: Aptar Pharma is a leading provider of drug delivery devices, dispensing systems, and active material science solutions for the pharmaceutical industry, including inhalation devices. Directly competes with Bespak in supplying inhalation and injectable drug delivery devices to pharmaceutical clients.
• Kindeva Drug Delivery: Kindeva Drug Delivery is a global CDMO specializing in inhalation and transdermal drug delivery, with significant pMDI and nasal spray manufacturing capabilities. Direct competitor to Bespak in the inhalation CDMO space, particularly for pMDIs.
• Nemera: Nemera is a drug delivery device company specializing in inhalation, injectable, and ophthalmic devices for pharmaceutical clients. Directly comparable to Bespak as a specialist drug delivery device manufacturer with inhalation focus.
• Vectura Group (Philip Morris International): Vectura was an inhalation drug delivery specialist CDMO, now part of Philip Morris International's wellness business. Was a direct competitor to Bespak in pMDI and DPI development and manufacturing before the acquisition.

Broad incumbents

• Catalent: Catalent is a large global CDMO with inhalation development and manufacturing capabilities among its broad service portfolio. Comparable to Bespak as a specialty inhalation manufacturer but operates at much larger scale across multiple dosage forms and therapeutic areas.
• Recipharm: Recipharm is a European CDMO offering inhalation and other pharmaceutical manufacturing services. Comparable to Bespak as a CDMO serving pharmaceutical clients, though with a broader service offering across multiple dosage forms.
• West Pharmaceutical Services: West Pharmaceutical Services is a global leader in drug delivery device manufacturing, including injectables and inhalation components. Comparable to Bespak as a drug delivery device manufacturer serving the pharmaceutical industry, though with a much larger product portfolio.
• Gerresheimer: Gerresheimer is a global manufacturer of pharmaceutical packaging and drug delivery devices including inhalers and injectables. Comparable to Bespak in serving pharmaceutical clients with drug delivery device manufacturing, though with broader packaging focus.
• Stevanato Group: Stevanato Group is a global provider of drug containment, drug delivery, and diagnostic solutions including injectable devices. Comparable to Bespak in drug delivery device manufacturing for pharmaceutical clients, with focus on injectables.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/bespak_
• Facebookfacebook.com/135449943151417
• LinkedInlinkedin.com/company/bespak

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bespak